Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Greene

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Oncology Letters|October 5, 2016
Inhibition of γ-secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T-cell acute lymphoblastic leukemia cells via upregulation of death receptor 5Lisa M Greene, Seema M Nathwani, Daniela M Zisterer
The Journal of Pharmacology and Experimental Therapeutics|September 11, 2015
Combretastatins: more than just vascular targeting agents?Lisa M Greene, Mary J Meegan, Daniela M Zisterer
EMBO Reports|December 4, 2003
Fibulins: physiological and disease perspectivesW Scott Argraves, Lisa M Greene, Marion A Cooley, et al.
Molecular Pharmacology|November 10, 2007
BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepinesLisa M Greene, Giuseppe Campiani, Mark Lawler, et al.
Biochemical Pharmacology|June 19, 2012
The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cellsLisa M Greene, Niamh M O'Boyle, Derek P Nolan, et al.
International Journal of Molecular Medicine|March 4, 2011
BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cellsLisa M Greene, Miriam Carr, Niall O Keeley, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 5, 2007
STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cellsLisa M Greene, Liam Kelly, Valeria Onnis, et al.
International Journal of Oncology|June 27, 2013
Inhibition of late-stage autophagy synergistically enhances pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon cancer cellsLisa M Greene, Derek P Nolan, Daniel Regan-Komito, et al.
European Journal of Medicinal Chemistry|October 12, 2010
Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effectsMiriam Carr, Lisa M Greene, Andrew J S Knox, et al.
Investigational New Drugs|February 21, 2018
Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cellsJade K Pollock, Lisa M Greene, Seema M Nathwani, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Oncology Letters|October 5, 2016
Inhibition of γ-secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T-cell acute lymphoblastic leukemia cells via upregulation of death receptor 5Lisa M Greene, Seema M Nathwani, Daniela M Zisterer
The Journal of Pharmacology and Experimental Therapeutics|September 11, 2015
Combretastatins: more than just vascular targeting agents?Lisa M Greene, Mary J Meegan, Daniela M Zisterer
EMBO Reports|December 4, 2003
Fibulins: physiological and disease perspectivesW Scott Argraves, Lisa M Greene, Marion A Cooley, et al.
Molecular Pharmacology|November 10, 2007
BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepinesLisa M Greene, Giuseppe Campiani, Mark Lawler, et al.
Biochemical Pharmacology|June 19, 2012
The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cellsLisa M Greene, Niamh M O'Boyle, Derek P Nolan, et al.
International Journal of Molecular Medicine|March 4, 2011
BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cellsLisa M Greene, Miriam Carr, Niall O Keeley, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 5, 2007
STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cellsLisa M Greene, Liam Kelly, Valeria Onnis, et al.
International Journal of Oncology|June 27, 2013
Inhibition of late-stage autophagy synergistically enhances pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon cancer cellsLisa M Greene, Derek P Nolan, Daniel Regan-Komito, et al.
European Journal of Medicinal Chemistry|October 12, 2010
Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effectsMiriam Carr, Lisa M Greene, Andrew J S Knox, et al.
Investigational New Drugs|February 21, 2018
Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cellsJade K Pollock, Lisa M Greene, Seema M Nathwani, et al.
Pageof 3